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OBJECTIVE: To assess the effect of short-term testoster-
one enanthanate (T) supplementation on health-related
quality of life (HRQOL) in healthy, elderly males.
METHODS: As part of a double-blind, placebo-con-
trolled study, 22 healthy males  65 years were random-
ized to receive a total of 4 doses of T 200 mg or placebo
(P) intramuscularly every 2 weeks. HRQOL was assessed
using the SF-36 and Psychological General Well-Being
(PGWB) scales at baseline and after 8 weeks. Data was
analyzed using unpaired and paired t-tests, adjusting for
covariates. The study had 80% power to detect a 20-
point difference in 4 of the SF-36 domains and the PGWB
score; a P-value 0.05 was considered statistically signif-
icant. RESULTS: The mean age in the T (n  14) and P
(n  8) groups was 73.1  3.1 and 70.1  4.2 years, re-
spectively. Baseline PGWB scores were similar between
the groups (T:93.2,P:92.1). Baseline SF-36 scores were
similar between the groups: physical functioning (PF)
(T:93.9,P:82.5), role-physical (RP) (T:92.9,P:93.8), bodily
pain (BP) (T:86.1,P:81.6), general health (GH) (T:84.4,
P:76.9), social functioning (SF) (T:99.1,P:95.3), role-
emotional (RE) (T:90.4,P:100.0) and mental health
(MH) (T:84.7,P:76.0,); only vitality (VT) was signifi-
cantly different at baseline (T:80.4,P:65.6; P  0.007).
After 8 weeks, SF-36 scores were similar between the
groups:- PF (T:96.5,P:91.7), RP (T:92.3,P:100.0), BP
(T:91.5,P:87.2,), GH (T:87.1,P:79.2), VT (T:80.0,P:74.2),
SF (T:96.2,P:100.0), RE (T:89.7,P:100.0), MH (T:88.1,
P:90.0). PGWB scores were not significantly different be-
tween the groups (T:95.0,P:95.8) and there was no signif-
icant change within each group in HRQOL scores over
time. CONCLUSION: Healthy males  65 years have
high baseline HRQOL scores which are not enhanced by
short-term testosterone supplementation.
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PRESCRIPTION DRUG USE DURING 
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The use of computerized databases to identify and follow
large cohorts of pregnant women make it feasible to
study trends in prescribing practices and to quickly iden-
tify defined cohorts of exposed pregnancies for further
research. OBJECTIVES: This study had two purposes, to
develop a methodology to identify pregnant women in an
automated database and determine the type and extent of
prescription drug use during a defined pregnancy period.
METHODS: A retrospective analysis of prescription
claims from an integrated managed care data base. The
study population consisted of women, aged 12–50 years
of age with a pregnancy indication during the period 10/
12/96–12/31/98. Pregnant women were identified using
ICD-9-CM diagnosis and procedure codes and CPT-4
codes. The pregnancy period was defined using date of
service fields. RESULTS: 4,732 women were identified
with a pregnancy during the specified time frame. 826
(17%) of these members had claims evidence of prescrip-
tion drug acquisition. Each woman received on average 2
different medications during pregnancy and an average
of 4.5 prescriptions. 25% of the prescription were agents
defined as pregnancy class C (prescription anthihistamine
agents, antiinfective agents and psychiatric medications
such as lithium and phenothiazines), 4% were defined as
pregnancy class D (antidepressant agents such as amitrip-
tyline and nortriptyline, anticonvulsant agents), and 7%
were classified as pregnancy class X (isotretinoin and es-
trogen preparations). Pregnancy class X poses the largest
concern. 115 women were identified with claims for oral
contraceptives that did not appear during the first or last
month of the pregnancy period. One woman was identi-
fied with claims for isotretinoin during the pregnancy pe-
riod. CONCLUSIONS: Information contained in the
claims data provides evidence regarding the use of pre-
scription drugs during pregnancy. Despite warnings in
literature and public media drugs defined as pregnancy
class X are acquired during the pregnancy period.
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DYSFUNCTION (ED): A REVIEW OF 
PUBLISHED RESULTS
Emery MP1, Kunle A1, Marquis P2, Sagnier PP3, Kubin M3
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Current trends in epidemiologic, economic and broader
effects of ED have implications for both public health
and patient QoL. Therefore evaluation of the impact of
the condition as well as new and competing treatments
must include assessment of QoL outcomes. Different
measures have been developed for assessing the impact of
ED and its treatments. Selection of one or more of these
measures for clinical research and practice must be based
on a careful comparison of published evidence of their
psychometric validity including responsiveness. OBJEC-
TIVES: To evaluate the psychometric properties and rele-
vance of measures used for assessing QoL in published
studies focusing on male sexual functioning in ill or well
subjects. METHODS: The literature search of MED-
LINE, EMBASE covered the period from 1966 to date
using various terms including QoL, satisfaction, impo-
tence and erectile dysfunction and was complemented by
a search of bibliographic data from our Information Re-
sources Center. RESULTS: 30 assessment tools have
been systematically reviewed in detail for their measure-
ment characteristics including psychometric properties.
These were made up of 19 sexuality/ED-specific mea-
sures, 3 generic multi-dimensional QoL instruments, 7
psychological scales and one satisfaction measure. We
found marked differences amongst instruments in terms
of domains covered and extent of psychometric valida-
tion of measures in the same taxonomic category. In par-
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ticular, only 5 of the 19 sexuality/ED-specific measures
adequately covered the conceptual domains of interest
while only 8 of them had adequate evidence of reliability,
validity and responsiveness. CONCLUSION: Our review
underscores the need for a careful examination of pub-
lished psychometric properties of instruments that are be-
ing considered for use even when they are claimed to
have been developed for persons with ED and related
sexual disorders.
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As the female population continues to live longer past
menopause, healthcare providers need to establish a pro-
active approach to the management of the menopausal
population in order to reduce long-term healthcare ex-
penditures. OBJECTIVE: The purpose of this analysis is
to assess the cost-effectiveness of hormone replacement
therapy (HRT) in peri-menopausal women of Belgium
and the United Kingdom. METHODS: A Markov model
was constructed to model treatment pathways and out-
comes of two cohorts. The model compares the health
and economic outcomes of women from age 53 through
94 treated with HRT versus those not treated with HRT.
The following “health states” were considered in the
model: well, osteoporosis-related fractures, coronary
heart disease, stroke, Alzheimer’s disease, breast cancer,
diabetes and death. A clinical management analysis de-
termined health care utilization for each “health state”,
while published epidemiologic estimates from each coun-
try, incorporating relative risk ratios, incidence and mor-
tality rates for each “health state” were entered into the
model. A resource valuation using country-specific inpa-
tient and outpatient costs were calculated for each
“health state”. RESULTS: Cost-effectiveness was mea-
sured as the incremental cost-per-life-year gained and the
incremental cost per event avoided. Assuming full com-
pliance with treatment in the HRT cohorts, the results
for Belgium and the United Kingdom indicate significant
reductions in episodes of disease. Furthermore, lifetime
expected costs per patient in the treated cohort decreased
with age while the lifetime costs of the untreated cohort
increased with age. A Monte Carlo analysis tested the
sensitivity of the model results. CONCLUSIONS: Hor-
mone replacement therapy is a more cost-effective means
of disease prevention when compared to no treatment
and should be considered by healthcare providers in Bel-
gium and the United Kingdom in the health management
of peri-menopausal populations.
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Benign Prostatic Hyperplasia (BPH) is common among
males in the Veterans Administration (VA) population.
The quality of life of such patients can decline signifi-
cantly since symptoms may interrupt normal daytime ac-
tivities or sleep, create anxiety, or reduce perception of
general health. Though clinical practice guidelines for the
management of BPH have been established, little research
has been done to determine adherence to such guidelines.
OBJECTIVE: To determine the preferences of urologists
in the management of BPH in the VA population to as-
sess compliance with established guidelines. METHODS:
A self-administered mail survey was sent to about 300
urologists providing services to the VA population in ap-
proximately 145 VA medical centers across the US. The
survey contained simulated cases of BPH patients, to de-
termine urologists’ preferences for diagnostic tests and
treatments recommended in the management of BPH.
The survey also gathered information on frequency of
failed initiation therapy and demographic and practice
information. The survey was pilot tested for face and
content validity among 10 urology residents. Descriptive
statistics will be used to analyze the level of agreement
among respondent urologists for diagnostic procedures
and treatments recommended. Differences based on de-
mographic and practice characteristics will also be deter-
mined. Urologists’ preferences will also be compared
with clinical guidelines and responses of an expert panel.
Failure rates for initiation therapy will also be deter-
mined using descriptive statistics. Published cost data for
various diagnostic procedures will be used to estimate the
mean cost of diagnosing BPH in the VA population.
CONCLUSION: Study results will help us better under-
stand how BPH is managed in the VA population.
Economic & Outcomes Research Methodological 
Issues PMT
PMT1
THE VALUE OF OBSERVATIONAL DATASETS IN 
THE ECONOMIC EVALUATION OF 
PHARMACEUTICALS: UK OBSERVATIONS
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OBJECTIVES: This research investigates the use of longi-
tudinal/cohort observational designs containing patient-
specific data for the economic evaluation of pharmaceuti-
cals in development or on the market, and appraises the
